Red Light Holland’s Psilocybin Microdosing Homogenized Capsules Receive Finalized Certificate of Analysis by CCREST Laboratories

• The natural psilocybin microdosing capsules, developed from psilocybin truffles grown in Red Light Holland’s farm in The Netherlands, have received the results of the successful final tests required for a Certificate of Analysis.

• Finalized Certificate of Analysis indicates Red Light Holland’s lab tested Truffles meets initial requirement for naturally occurring medical grade microdosing capsules, which NUBU Pharmaceuticals aim to distribute in Australia and New Zealand.

Toronto, Ontario–(Newsfile Corp. – August 1, 2023) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company”), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, is excited to announce successful updates regarding its manufacturing plans to create homogenized natural psilocybin microdosing capsules. Further to the announcement on June 19, 2023, CCrest Laboratories Inc. (“CCrest Laboratories”), a Montreal-based cGMP pharmaceutical laboratory that holds a Controlled Drugs & Substances Dealer’s License from Health Canada, have finished the final tests required for a full certificate of analysis (“COA”) of the capsules developed from Red Light Hollands psilocybin truffles grown in their farm in The Netherlands and imported to Canada under a Health Canada approved psilocybin import license. These final tests have confirmed there are no pesticides or heavy metals in the capsules and that they are free from biocontaminants.

As disclosed previously, the natural psilocybin microdosing capsules are intended to be distributed in Australasia by NUBU Pharmaceuticals (“NUBU Pharmaceuticals”), a leading medical cannabis company based in New Zealand with distribution ties to Australia. With the finalized COA, Red Light Holland has now met the requirements needed by NUBU Pharmaceuticals for furthering the goal of distribution, due to the successful results from CCREST, a cGMP testing facility operating under Health Canada licenses which offers extensive chemistry and microbiology testing, stability studies, method development and COA validation.

“This is a very significant day – receiving a finalized COA on our naturally occurring grown psilocybin is quite an achievement. Red Light Holland continues to be innovative and groundbreaking. Our goal to produce an excellent standardized natural psilocybin microdosing product that could potentially help many people in new emerging legal markets, is now one step closer. Quite honestly – we are very proud of how far we’ve come, even though there are still future steps to tackle.” said Todd Shapiro, Red Light Holland CEO and Director. “Our great partnership continues to be novel in the psychedelic industry and as far as we know, we are the first company to develop homogenized microdosing capsules from natural psilocybin truffles that have passed through these rigorous tests by regulated labs with qualified technicians.”

“The success of Red Light Holland’s psilocybin microdosing homogenized capsules receiving a finalized COA is very exciting and we are quite pleased with the successful results to date. This is an important stage in developing high quality microdosing capsules with our combined efforts of creating a safe and effective naturally occurring product, as opposed to synthetics, that can hopefully help people and contribute to positive change while hopefully ending stigmas around psychedelics,” said Alex Grenier, CEO of Shaman Pharma and President of CCrest Laboratories.

Updates on the results of the capsules’ stability tests are expected in the near future.

Australia has recently, on February 3, 2023, announced a down-listing of psilocybin in its list of controlled substances to allow psychiatrists to prescribe psilocybin to patients suffering from treatment resistant depression. The change in scheduling was announced to take effect on July 1, 2023. Red Light Holland and NUBU Pharmaceuticals will work together in efforts to help people in Australia and New Zealand through NUBU Pharmaceuticals’ vast network of Doctors and connections with Health Regulators in both New Zealand and Australia.

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co

About Shaman Pharma Corp.

Shaman Pharma is a federally registered Canadian corporation with the mission to power outstanding psychedelic life science innovation. Accelerating time-to-market through its portfolio of assets, Shaman launches and consolidates revenue-driven pharma-biotech life sciences ventures focused on supplying psychedelic drugs & novel active ingredients.

About NUBU Pharmaceuticals

Formed in 2017, NUBU Pharmaceuticals (New Zealand’s largest medicinal cannabis distribution company) specializes in the distribution of therapeutics from the new frontier of medicine, including cannabis and psychedelics. The company also develops New Zealand-made cannabis products for export markets, harnessing two of New Zealand’s great strengths, it’s innovative culture and unique botanicals.

For additional information on the Company:

Mark Dye
Co-Founder/Chief Executive Officer
Tel: +649-360 0204
Email: mark.dye@nubupharma.com
Website: www.nubupharma.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events.

The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company’s performance, business objectives and milestones and the anticipated timing thereof, and costs in connection with, the execution or achievement of such objectives and milestones, including its plans to continue seeking legal opportunities to increase responsible access to natural psilocybin around the world and NUBU Pharmaceutical’s distribution of the Company’s microsdosing capsules in Australasia; the Company and the Company’s partners, including NUBU Pharmaceuticals and CCrest Laboratories, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described, including bringing a microdosing product that has the potential of helping many people; complete stability tests; certificate of analysis meeting requirements for medical grad Government of Australia to down list psilocybin under its controlled substances list and under the stated timelines; the Company’s continued commitment to its products for microdosing that can potentially be accessible in emerging legal markets worldwide; and that the Company will provide updates with respect to its continued work with its partners on the microdosing capsules.

Forward-looking information in this press release are based on certain assumptions and expected future events, namely: the Company’s ability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company’s partners’ abilities, including NUBU Pharmaceuticals and CCrest Laboratories, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; Complete stability tests. the ability of the Government of Australia to down list psilocybin under its controlled substances list and under the stated timelines; the Company’s ability to continue developing its products for microdosing that can potentially be accessible in emerging legal markets worldwide; and the Company’s ability to provide updates with respect to its continued work with its partners on the microdosing capsules.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company’s partners’ inabilities, including NUBU Pharmaceuticals and CCrest Laboratories, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the inability for the Company to export it homogenized microdosing capsules, the potential for NUBU Pharmaceuticals to accept the COA by CCrest labs, the inability of the Government of Australia or Government of New Zealand to down list psilocybin under its controlled substances list and under the stated timelines; the Company’s inability to continue developing its products for microdosing that can potentially be accessible in emerging legal markets worldwide; and the Company’s inability to provide updates with respect to its continued work with its partners on the microdosing capsules.

Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/175639